Healome Therapeutics raises €1.4M Series A round
28 November 2025· Birmingham, United Kingdom· health, biotech, materials, b2b, deep_hardware
The funding will be used to support further pre-clinical testing and progress towards Phase I clinical trials for its fluid-gel ocular treatments.
Investors
LeadEmpirical Ventures
Also participating
SFC CapitalInnovate UKUniversity of BirminghamNational Institute for Health and Care ResearchCure EBAbe Fund
About Healome Therapeutics
Stage
Series A
Headquarters
Birmingham, United Kingdom
Founded
2021
Team Size
1–5
Sectors
healthbiotechmaterialsb2bdeep_hardware